STOCK TITAN

Relmada (NASDAQ: RLMD) holders back higher share cap and equity plan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. reported that stockholders approved a Charter Amendment increasing authorized common shares from 150,000,000 to 200,000,000. This expands the company’s capacity to issue new stock in the future for financing, compensation, or other corporate purposes.

At the 2026 Annual Meeting, 66,571,711 of 104,888,223 eligible common shares, or about 63.47%, were represented. Stockholders elected two Class II directors, ratified CBIZ CPAs P.C. as independent auditor for 2026, and approved an amendment to the 2021 Equity Incentive Plan, lifting its share pool by 3,000,000 to a total of 18,052,942 shares.

Positive

  • None.

Negative

  • None.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Authorized common shares after amendment 200,000,000 shares Charter Amendment approved at 2026 Annual Meeting
Authorized common shares before amendment 150,000,000 shares Prior Articles of Incorporation level
Shares outstanding and eligible to vote 104,888,223 shares Common stock eligible at 2026 Annual Meeting
Shares represented at meeting 66,571,711 shares (63.47%) Present in person or by proxy at Annual Meeting
Equity plan pool increase 3,000,000 shares Additional shares for 2021 Equity Incentive Plan
Total 2021 Plan share pool 18,052,942 shares Aggregate shares available including previous grants
Votes for Charter Amendment 65,072,921 votes Proposal 4 For votes to increase authorized shares
Votes for auditor ratification 66,097,327 votes For votes on CBIZ CPAs P.C. as 2026 auditor
Charter Amendment regulatory
"to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “Charter Amendment”)."
A charter amendment is a formal change to a corporation’s founding document — its legal rulebook that sets basic structure, powers and shareholder rights. Investors care because amending the charter can alter voting rules, share classes, dividend policies or takeover protections, which can change how value and control are distributed; think of it as revising a building’s blueprint that affects who owns which rooms and who can remodel next.
2021 Equity Incentive Plan financial
"to increase the number of shares of the Company’s common stock available for issuance pursuant to awards under the 2021 Plan by 3,000,000"
independent registered public accounting firm financial
"ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"For | | Against | | Withheld | | Broker Non-Votes 65,072,921 | | 1,170,378 | | 328,412 | | -"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
authorized shares financial
"to increase the number of authorized shares of common stock from 150,000,000 to 200,000,000."
Authorized shares are the maximum number of shares a company is allowed to issue according to its official plan. Think of it as a company’s set limit on how many pieces of its ownership it can distribute to investors. This number helps investors understand the potential for future growth or change in the company's ownership structure.
false --12-31 0001553643 0001553643 2026-05-27 2026-05-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 27, 2026

 

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-39082   45-5401931
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

2222 Ponce de Leon Blvd., Floor 3

Coral GablesFL

  33134
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (786629-1376

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol    Name of exchange on which registered
Common stock, $0.001 par value per share   RLMD   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “Charter Amendment”).

 

The Charter Amendment was approved by the Company’s stockholders at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). held on May 27, 2026. The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On May 27, 2026, the Company held its Annual Meeting. Of the 104,888,223 shares of the Company’s common stock outstanding and eligible to vote at the Annual Meeting, 66,571,711 shares, or approximately 63.47% of the eligible common stock, were present either in person or by proxy and voted. The final results of the matters voted on at the Annual Meeting are provided below.

 

Proposal 1: Election of Directors.

 

Stockholders elected the following nominees as directors to hold office until the 2029 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified or until his earlier resignation or removal.

 

Nominee  For   Withheld   Broker
Non-Votes
 
Charles J. Casamento (Class II, 36 month term)   33,859,106    20,888,478    11,824,127 
Sergio Traversa (Class II, 36 month term)   54,124,764    622,820    11,824,127 

 

The continuing Class I Director is Fabiana Fedeli. The continuing Class III Directors are Paul Kelly and John Glasspool.

 

Proposal 2: Ratification of Appointment of Independent Auditors.

 

Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

 

For  Against  Withheld  Broker Non-Votes
66,097,327  104,854  369,530  -

 

Proposal 3: Approval of an Amendment to the 2021 Plan.

 

Stockholders approved the proposed amendment to the Company’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”), to increase the number of shares of the Company’s common stock available for issuance pursuant to awards under the 2021 Plan by 3,000,000 to an aggregate of 18,052,942 (including awards previously granted). The 2021 Plan is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026.

 

For   Against   Withheld   Broker Non-Votes
36,480,855   18,181,681   85,048   11,824,127

 

Proposal 4:   Approval of the Charter Amendment

 

Stockholders approved the proposed amendment to the Company’s Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 150,000,000 to 200,000,000. The Charter Amendment is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026

 

For   Against   Withheld   Broker Non-Votes
65,072,921   1,170,378   328,412   -

  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
3.1   Certificate of Amendment to Articles of Incorporation
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 28, 2026 RELMADA THERAPEUTICS, INC.
     
  By: /s/ Sergio Traversa
  Name:  Sergio Traversa
  Title: Chief Executive Officer

 

2

 

FAQ

What change did Relmada Therapeutics (RLMD) make to its authorized common shares?

Relmada increased its authorized common stock from 150,000,000 to 200,000,000 shares. This Charter Amendment gives the company more flexibility to issue stock for capital raising, acquisitions, or equity compensation without needing another charter change.

How many Relmada (RLMD) shares were eligible and represented at the 2026 Annual Meeting?

There were 104,888,223 common shares outstanding and eligible to vote, with 66,571,711 shares represented, or about 63.47%. This level of participation provided a sufficient base for stockholders to validly approve the proposals presented at the meeting.

What happened to Relmada’s 2021 Equity Incentive Plan at the 2026 meeting?

Stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing shares available for issuance by 3,000,000 to an aggregate of 18,052,942. This larger pool supports future equity awards to employees, directors, and other service providers under the plan.

Which directors were elected at Relmada Therapeutics’ 2026 Annual Meeting?

Stockholders elected Charles J. Casamento and Sergio Traversa as Class II directors to serve until the 2029 Annual Meeting. Existing Class I director Fabiana Fedeli and Class III directors Paul Kelly and John Glasspool continue in their current board roles.

Did Relmada (RLMD) stockholders ratify the company’s independent auditor for 2026?

Stockholders ratified CBIZ CPAs P.C. as Relmada’s independent registered public accounting firm for the year ending December 31, 2026. The vote was strongly in favor, with 66,097,327 votes for, 104,854 against, and 369,530 withheld, and no broker non-votes.

How strongly was Relmada’s Charter Amendment to increase authorized shares approved?

The Charter Amendment increasing authorized common shares to 200,000,000 received 65,072,921 votes for, 1,170,378 against, and 328,412 withheld. There were no broker non-votes, indicating broad support among voting stockholders for expanding authorized share capacity.

Filing Exhibits & Attachments

4 documents